HRP20110834T1 - Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida - Google Patents
Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida Download PDFInfo
- Publication number
- HRP20110834T1 HRP20110834T1 HR20110834T HRP20110834T HRP20110834T1 HR P20110834 T1 HRP20110834 T1 HR P20110834T1 HR 20110834 T HR20110834 T HR 20110834T HR P20110834 T HRP20110834 T HR P20110834T HR P20110834 T1 HRP20110834 T1 HR P20110834T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridine
- imidazo
- derivative according
- dihydro
- dione
- Prior art date
Links
- HAIALLMLSNZDAL-UHFFFAOYSA-N 3-methylidenepyrrolidin-2-one;pyridine Chemical class C1=CC=NC=C1.C=C1CCNC1=O HAIALLMLSNZDAL-UHFFFAOYSA-N 0.000 title claims abstract 24
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003906 phosphoinositides Chemical class 0.000 title 1
- 206010052779 Transplant rejections Diseases 0.000 claims abstract 3
- 208000036142 Viral infection Diseases 0.000 claims abstract 3
- 230000001580 bacterial effect Effects 0.000 claims abstract 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract 3
- 230000009385 viral infection Effects 0.000 claims abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 208000035143 Bacterial infection Diseases 0.000 claims abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 208000004852 Lung Injury Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 208000017169 kidney disease Diseases 0.000 claims abstract 2
- 231100000515 lung injury Toxicity 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 238000002054 transplantation Methods 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- JGPZTXGXPQLUNK-WQLSENKSSA-N (5z)-5-[(4-piperidin-1-ylpyrido[3,2-d]pyrimidin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CN=C2N3CCCCC3)C2=N1 JGPZTXGXPQLUNK-WQLSENKSSA-N 0.000 claims 1
- XBJMHPNTDYFYPN-GHXNOFRVSA-N (5z)-5-[[4-(4-fluoropiperidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1CC(F)CCN1C(C1=N2)=NC=NC1=CC=C2\C=C/1C(=O)NC(=O)S\1 XBJMHPNTDYFYPN-GHXNOFRVSA-N 0.000 claims 1
- SHJWCNWPFZYSSY-GHXNOFRVSA-N (5z)-5-[[4-[4-(trifluoromethyl)piperidin-1-yl]pyrido[3,2-d]pyrimidin-6-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1CC(C(F)(F)F)CCN1C(C1=N2)=NC=NC1=CC=C2\C=C/1C(=O)NC(=O)S\1 SHJWCNWPFZYSSY-GHXNOFRVSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- KUFUQTGFDHXFKT-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1h-imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=O)N=C2N1 KUFUQTGFDHXFKT-UHFFFAOYSA-N 0.000 claims 1
- UAWVYQKZKQKNLK-UHFFFAOYSA-N 2-trimethylsilylfuro[3,2-b]pyridine-5-carbaldehyde Chemical compound O=CC1=CC=C2OC([Si](C)(C)C)=CC2=N1 UAWVYQKZKQKNLK-UHFFFAOYSA-N 0.000 claims 1
- IULMQUJQLRQXRT-UHFFFAOYSA-N 3-(1-acetyl-2,3-dihydroindol-5-yl)imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2N(C(=O)C)CCC2=C1 IULMQUJQLRQXRT-UHFFFAOYSA-N 0.000 claims 1
- WVTSSDODNQXOIZ-UHFFFAOYSA-N 3-(1-methylsulfonyl-2,3-dihydroindol-5-yl)imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2N(S(=O)(=O)C)CCC2=C1 WVTSSDODNQXOIZ-UHFFFAOYSA-N 0.000 claims 1
- QMFHCAVUJVOBBI-UHFFFAOYSA-N 3-(1-methylsulfonyl-2,3-dihydroindol-6-yl)imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2CCN(S(=O)(=O)C)C2=C1 QMFHCAVUJVOBBI-UHFFFAOYSA-N 0.000 claims 1
- GRSCFKHCLLTKOT-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound COC1=CC(OC)=CC(N2C3=NC(C=O)=CC=C3N=C2)=C1 GRSCFKHCLLTKOT-UHFFFAOYSA-N 0.000 claims 1
- RNIOKEAHHAAMJS-UHFFFAOYSA-N 3-[1-(3-morpholin-4-ylpropylsulfonyl)-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C12=NC(C=O)=CC=C2N=CN1C(C=C1CC2)=CC=C1N2S(=O)(=O)CCCN1CCOCC1 RNIOKEAHHAAMJS-UHFFFAOYSA-N 0.000 claims 1
- GLVSYGRJYMCWIG-UHFFFAOYSA-N 3-[1-(chloromethylsulfonyl)-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2N(S(=O)(=O)CCl)CCC2=C1 GLVSYGRJYMCWIG-UHFFFAOYSA-N 0.000 claims 1
- RFUVXPDMMPOWIP-UHFFFAOYSA-N 3-[1-[4-(dimethylamino)butanoyl]-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2N(C(=O)CCCN(C)C)CCC2=C1 RFUVXPDMMPOWIP-UHFFFAOYSA-N 0.000 claims 1
- NZMJEUBOVHCHMJ-UHFFFAOYSA-N 3-phenyl-1,2-dihydroimidazo[4,5-b]pyridine-5-carbaldehyde Chemical compound C12=NC(C=O)=CC=C2NCN1C1=CC=CC=C1 NZMJEUBOVHCHMJ-UHFFFAOYSA-N 0.000 claims 1
- JTFCVFBIUJZTBF-UHFFFAOYSA-N 4-(4-fluoropiperidin-1-yl)pyrido[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C1CC(F)CCN1C1=NC=NC2=CC=C(C=O)N=C12 JTFCVFBIUJZTBF-UHFFFAOYSA-N 0.000 claims 1
- JDTXUYSJHLUHCD-UHFFFAOYSA-N 4-(4-methylpiperidin-1-yl)pyrido[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C1CC(C)CCN1C1=NC=NC2=CC=C(C=O)N=C12 JDTXUYSJHLUHCD-UHFFFAOYSA-N 0.000 claims 1
- OFUADGZFYGQFPN-UHFFFAOYSA-N 4-piperidin-1-ylpyrido[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C12=NC(C=O)=CC=C2N=CN=C1N1CCCCC1 OFUADGZFYGQFPN-UHFFFAOYSA-N 0.000 claims 1
- OVJMADOUAZUMBK-UHFFFAOYSA-N 5-(furo[3,2-b]pyridin-5-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=C(OC=C2)C2=N1 OVJMADOUAZUMBK-UHFFFAOYSA-N 0.000 claims 1
- AHTZAQDEHIELJR-UHFFFAOYSA-N 5-(pyrido[2,3-b]pyrazin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=C(N=CC=N2)C2=N1 AHTZAQDEHIELJR-UHFFFAOYSA-N 0.000 claims 1
- QZIMBEUANISWPZ-UHFFFAOYSA-N 5-[(3-phenylimidazo[4,5-b]pyridin-5-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=C(N=CN2C=3C=CC=CC=3)C2=N1 QZIMBEUANISWPZ-UHFFFAOYSA-N 0.000 claims 1
- DHZGQXLOFLEOFV-UHFFFAOYSA-N 5-[[3-(1-acetyl-2,3-dihydroindol-5-yl)imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C2N(C(=O)C)CCC2=CC=1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O DHZGQXLOFLEOFV-UHFFFAOYSA-N 0.000 claims 1
- NUFGAQIKNRMGRQ-UHFFFAOYSA-N 5-[[3-(1-methylsulfonyl-2,3-dihydroindol-5-yl)imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C2N(S(=O)(=O)C)CCC2=CC=1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O NUFGAQIKNRMGRQ-UHFFFAOYSA-N 0.000 claims 1
- ORXFEMFHIJENGK-UHFFFAOYSA-N 5-[[3-(1-methylsulfonyl-2,3-dihydroindol-6-yl)imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(S(=O)(=O)C)CCC2=CC=C1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O ORXFEMFHIJENGK-UHFFFAOYSA-N 0.000 claims 1
- RTDWUOWYODSBQO-UHFFFAOYSA-N 5-[[3-(2,3-dihydro-1h-indol-5-yl)imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=C(N=CN2C=3C=C4CCNC4=CC=3)C2=N1 RTDWUOWYODSBQO-UHFFFAOYSA-N 0.000 claims 1
- HTILVLJWRQZACK-UHFFFAOYSA-N 5-[[3-(3,5-dimethoxyphenyl)imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound COC1=CC(OC)=CC(N2C3=NC(C=C4C(NC(=O)S4)=O)=CC=C3N=C2)=C1 HTILVLJWRQZACK-UHFFFAOYSA-N 0.000 claims 1
- RZBZZQNKTLLNRP-UHFFFAOYSA-N 5-[[3-[1-(3-morpholin-4-ylpropylsulfonyl)-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1=CC1=CC=C(N=CN2C=3C=C4CCN(C4=CC=3)S(=O)(=O)CCCN3CCOCC3)C2=N1 RZBZZQNKTLLNRP-UHFFFAOYSA-N 0.000 claims 1
- XIBLLEAUWMHTJH-UHFFFAOYSA-N 5-[[3-[1-(chloromethylsulfonyl)-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C2N(S(=O)(=O)CCl)CCC2=CC=1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O XIBLLEAUWMHTJH-UHFFFAOYSA-N 0.000 claims 1
- FCXHYKOBMZPFQB-UHFFFAOYSA-N 5-[[3-[1-[4-(dimethylamino)butanoyl]-2,3-dihydroindol-5-yl]imidazo[4,5-b]pyridin-5-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C2N(C(=O)CCCN(C)C)CCC2=CC=1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O FCXHYKOBMZPFQB-UHFFFAOYSA-N 0.000 claims 1
- HQLYFLIKOWCSNS-UHFFFAOYSA-N 5-[[4-(4-fluoropiperidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CC(F)CCN1C(C1=N2)=NC=NC1=CC=C2C=C1C(=O)NC(=S)S1 HQLYFLIKOWCSNS-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 231100000516 lung damage Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- FQVPEJDAEZBQRA-UHFFFAOYSA-N pyrido[2,3-b]pyrazine-6-carbaldehyde Chemical compound N1=CC=NC2=NC(C=O)=CC=C21 FQVPEJDAEZBQRA-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- IEXWGFFNEZZXDM-UHFFFAOYSA-N tert-butyl 5-(5-formylimidazo[4,5-b]pyridin-3-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2N(C(=O)OC(C)(C)C)CCC2=C1 IEXWGFFNEZZXDM-UHFFFAOYSA-N 0.000 claims 1
- NOHUTZOOKJYMCB-UHFFFAOYSA-N tert-butyl 5-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]imidazo[4,5-b]pyridin-3-yl]-2,3-dihydroindole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)CCC2=CC=1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O NOHUTZOOKJYMCB-UHFFFAOYSA-N 0.000 claims 1
- BLTPCGKNFIOYQZ-UHFFFAOYSA-N tert-butyl 6-(5-formylimidazo[4,5-b]pyridin-3-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C1=NC2=CC=C(C=O)N=C2N1C1=CC=C2CCN(C(=O)OC(C)(C)C)C2=C1 BLTPCGKNFIOYQZ-UHFFFAOYSA-N 0.000 claims 1
- JRILAWQKEXMNIC-UHFFFAOYSA-N tert-butyl 6-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]imidazo[4,5-b]pyridin-3-yl]-2,3-dihydroindole-1-carboxylate Chemical compound C1=C2N(C(=O)OC(C)(C)C)CCC2=CC=C1N(C1=N2)C=NC1=CC=C2C=C1SC(=O)NC1=O JRILAWQKEXMNIC-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60737404P | 2004-09-03 | 2004-09-03 | |
| EP04104259 | 2004-09-03 | ||
| PCT/EP2005/054339 WO2006024666A1 (en) | 2004-09-03 | 2005-09-02 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110834T1 true HRP20110834T1 (hr) | 2011-12-31 |
Family
ID=35457295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110834T HRP20110834T1 (hr) | 2004-09-03 | 2011-11-11 | Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7842698B2 (no) |
| EP (1) | EP1786812B1 (no) |
| JP (1) | JP5209311B2 (no) |
| KR (1) | KR101229647B1 (no) |
| CN (1) | CN101052640B (no) |
| AT (1) | ATE532783T1 (no) |
| AU (1) | AU2005279156B2 (no) |
| BR (1) | BRPI0515627A (no) |
| CA (1) | CA2576765C (no) |
| CY (1) | CY1112316T1 (no) |
| EA (1) | EA012178B1 (no) |
| HK (1) | HK1106773A1 (no) |
| HR (1) | HRP20110834T1 (no) |
| IL (1) | IL181415A (no) |
| MX (1) | MX2007002604A (no) |
| NO (1) | NO20071605L (no) |
| PL (1) | PL1786812T3 (no) |
| SI (1) | SI1786812T1 (no) |
| WO (1) | WO2006024666A1 (no) |
| ZA (1) | ZA200701666B (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2531140C (en) | 2003-07-28 | 2013-06-18 | Applied Research Systems Ars Holding N.V. | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| US20090215818A1 (en) * | 2006-07-24 | 2009-08-27 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as pi3 kinase inhibitors |
| JP5507543B2 (ja) * | 2008-04-29 | 2014-05-28 | ノバルティス アーゲー | アクチビン様受容体キナーゼ（ａｌｋ４またはａｌｋ５）阻害剤としてのイミダゾ−ピリジン誘導体 |
| WO2010030727A1 (en) * | 2008-09-10 | 2010-03-18 | Wyeth Llc | 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| KR20110115160A (ko) * | 2009-02-12 | 2011-10-20 | 메르크 세로노 에스. 에이. | 2-모르폴리노-피리도〔3,2-ｄ〕피리미딘 |
| PL2509602T3 (pl) * | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| CN102884062B (zh) | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| AU2012245344B2 (en) | 2011-04-22 | 2017-11-09 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2763673B1 (en) * | 2011-09-15 | 2018-08-01 | Taipei Medical University | Use of indolyl hydroxamates for treating heart failure or neuronal injury |
| TW201319063A (zh) * | 2011-10-04 | 2013-05-16 | Yakult Honsha Kk | 以四氫噻唑衍生物或其鹽為有效成分之醫藥品 |
| KR101990605B1 (ko) | 2011-11-04 | 2019-06-18 | 자스코 파머수티컬스, 엘엘씨 | 아미노피리미딘 키나아제 억제제 |
| KR101684950B1 (ko) | 2012-07-23 | 2016-12-12 | 주식회사유한양행 | 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물 |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| AU2016255434C1 (en) * | 2015-04-29 | 2021-09-23 | Rapport Therapeutics, Inc. | Azabenzimidazoles and their use as AMPA receptor modulators |
| CA2984305C (en) | 2015-04-29 | 2021-12-28 | Janssen Pharmaceutica Nv | Indolone compounds and their use as ampa receptor modulators |
| AU2016255424B2 (en) | 2015-04-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators |
| WO2016176457A1 (en) | 2015-04-29 | 2016-11-03 | Janssen Pharmaceutica Nv | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| CN106588909B (zh) * | 2017-01-06 | 2019-08-27 | 广东工业大学 | 一种喹啉类衍生物的制备及其在抗炎中的应用 |
| CN109575435A (zh) | 2017-09-14 | 2019-04-05 | 株式会社日化精密科技 | 聚丙烯树脂组合物、聚丙烯树脂成形体以及聚丙烯树脂成形体的制造方法 |
| EP4434972A1 (en) | 2023-03-22 | 2024-09-25 | Eberhard-Karls-Universität Tübingen | Atm kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS115904A (en) * | 2002-07-10 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused benzene derivatives |
| AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| AU2003303231A1 (en) | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
| CA2531140C (en) | 2003-07-28 | 2013-06-18 | Applied Research Systems Ars Holding N.V. | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| EP1758895A1 (en) * | 2004-06-17 | 2007-03-07 | Wyeth a Corporation of the State of Delaware | Gonadotropin releasing hormone receptor antagonists |
| ZA200702435B (en) * | 2004-10-12 | 2008-06-25 | Serono Lab | PI3 Kinase gamma inhibitors for the treatment of anaemia |
| EP1931424A2 (en) * | 2005-09-07 | 2008-06-18 | Laboratoires Serono S.A. | P13k inhibitors for the treatment of endometriosis |
| TW200808793A (en) * | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US20100063066A1 (en) * | 2006-08-31 | 2010-03-11 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| CN101743007B (zh) * | 2007-07-12 | 2015-04-08 | 南佛罗里达大学 | 具有抗肿瘤活性的akt/pkb抑制剂 |
| US7932251B2 (en) * | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
-
2005
- 2005-09-02 KR KR1020077007588A patent/KR101229647B1/ko not_active IP Right Cessation
- 2005-09-02 PL PL05797231T patent/PL1786812T3/pl unknown
- 2005-09-02 US US11/574,613 patent/US7842698B2/en not_active Expired - Fee Related
- 2005-09-02 AT AT05797231T patent/ATE532783T1/de active
- 2005-09-02 JP JP2007528883A patent/JP5209311B2/ja not_active Expired - Fee Related
- 2005-09-02 AU AU2005279156A patent/AU2005279156B2/en not_active Ceased
- 2005-09-02 EA EA200700541A patent/EA012178B1/ru not_active IP Right Cessation
- 2005-09-02 CN CN200580037159XA patent/CN101052640B/zh not_active Expired - Fee Related
- 2005-09-02 MX MX2007002604A patent/MX2007002604A/es active IP Right Grant
- 2005-09-02 WO PCT/EP2005/054339 patent/WO2006024666A1/en active Application Filing
- 2005-09-02 SI SI200531418T patent/SI1786812T1/sl unknown
- 2005-09-02 CA CA2576765A patent/CA2576765C/en not_active Expired - Fee Related
- 2005-09-02 ZA ZA200701666A patent/ZA200701666B/en unknown
- 2005-09-02 BR BRPI0515627-0A patent/BRPI0515627A/pt not_active IP Right Cessation
- 2005-09-02 EP EP05797231A patent/EP1786812B1/en active Active
-
2007
- 2007-02-19 IL IL181415A patent/IL181415A/en not_active IP Right Cessation
- 2007-03-27 NO NO20071605A patent/NO20071605L/no not_active Application Discontinuation
-
2008
- 2008-01-16 HK HK08100536.3A patent/HK1106773A1/xx not_active IP Right Cessation
-
2010
- 2010-10-18 US US12/906,729 patent/US8058289B2/en not_active Expired - Fee Related
-
2011
- 2011-11-11 HR HR20110834T patent/HRP20110834T1/hr unknown
-
2012
- 2012-02-02 CY CY20121100119T patent/CY1112316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080269227A1 (en) | 2008-10-30 |
| JP2008511589A (ja) | 2008-04-17 |
| IL181415A (en) | 2012-09-24 |
| CY1112316T1 (el) | 2015-12-09 |
| ZA200701666B (en) | 2008-07-30 |
| ATE532783T1 (de) | 2011-11-15 |
| CA2576765C (en) | 2013-05-28 |
| EA012178B1 (ru) | 2009-08-28 |
| CA2576765A1 (en) | 2006-03-09 |
| EA200700541A1 (ru) | 2007-08-31 |
| CN101052640A (zh) | 2007-10-10 |
| US7842698B2 (en) | 2010-11-30 |
| CN101052640B (zh) | 2011-05-11 |
| SI1786812T1 (sl) | 2011-12-30 |
| KR20070053315A (ko) | 2007-05-23 |
| JP5209311B2 (ja) | 2013-06-12 |
| AU2005279156B2 (en) | 2011-06-02 |
| BRPI0515627A (pt) | 2008-07-29 |
| KR101229647B1 (ko) | 2013-02-05 |
| IL181415A0 (en) | 2007-07-04 |
| EP1786812A1 (en) | 2007-05-23 |
| PL1786812T3 (pl) | 2012-04-30 |
| MX2007002604A (es) | 2007-04-25 |
| EP1786812B1 (en) | 2011-11-09 |
| HK1106773A1 (en) | 2008-03-20 |
| US20110034458A1 (en) | 2011-02-10 |
| US8058289B2 (en) | 2011-11-15 |
| AU2005279156A1 (en) | 2006-03-09 |
| NO20071605L (no) | 2007-05-31 |
| WO2006024666A1 (en) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110834T1 (hr) | Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida | |
| CA2902103C (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| ES2581848T3 (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina | |
| HRP20150082T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| KR101381092B1 (ko) | 헤테로시클릭 야누스 키나제 ３ 억제제 | |
| KR102319857B1 (ko) | P2x7 조절제 | |
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| CA3085942A1 (en) | Aryl and heteroaryl substituted indole compounds | |
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| JP2014528482A5 (no) | ||
| JP2019536768A5 (no) | ||
| RU2014119244A (ru) | Гетероциклические соединения и способы их использования | |
| HRP20160890T1 (hr) | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja | |
| JP2013515729A5 (no) | ||
| AU2005268845A1 (en) | Condensed pyridines as kinase inhibitors | |
| JP2007521287A5 (no) | ||
| HRP20141029T1 (hr) | Derivati pirazolopiridina kao inhibitori nadph oksidaze | |
| JP2010534646A5 (no) | ||
| CA2532122A1 (fr) | Tetrahydro-1h-pyrazolo[3,4-c]pyridines substituees, compositions les contenant et utilisation | |
| JP2005526029A (ja) | 細胞増殖が関与する疾患を治療するためのキノリノン誘導体 | |
| CA3027814A1 (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as intermediates for type iii receptor tyrosine kinase inhibitors | |
| CA3136324A1 (en) | Acss2 inhibitors and methods of use thereof | |
| JP2018525377A5 (no) | ||
| JP2011525183A (ja) | キナーゼ阻害剤として有用なイミダゾピリジンおよびイミダゾピラジン化合物 | |
| RU2008115499A (ru) | Новые производные аминокиламидов в качестве антагонистов лигандов рецепторов ccr3 |